IAMA-X

IAMA-X is a preclinical-stage drug candidate or series of backup compounds being developed by IAMA Therapeutics. It is part of the company's research and development pipeline focused on modulating cation-chloride cotransporters (CCCs) to treat central nervous system (CNS) disorders. While specific details regarding its molecular structure and primary indication are not publicly disclosed, it is intended to follow or support the lead candidate IAMA-6, which is a small molecule inhibitor of the Na-K-2Cl cotransporter 1 (NKCC1). The program targets conditions characterized by neuronal chloride imbalance, such as drug-resistant epilepsy, autism spectrum disorder, and other neurodevelopmental or neuropsychiatric conditions.